Transforming the lives of patients with inflammatory disease and cancer.


Mestag Therapeutics was founded in 2020 by leading scientists, drug developers and investors to pioneer new medicines for people affected by inflammatory disease and cancer.

Our approach builds on recent data which points to resident cells called fibroblasts as playing a key role in driving disease. Mestag’s mission is to lead this emerging field in developing impactful precision medicines for patients through our understanding of activated fibroblast populations and their influence on immune effector cells.

Our company was created by global thought-leaders in fibroblast biology, is supported by experienced international investors and is powered by our team of scientists based in Cambridge, UK.


Fierce 15 2021

In September 2021 Mestag was named by Fierce Biotech as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

View the Mestag press release HERE

View the Fierce Biotech coverage HERE